logo

For the Inventor, By the Inventor

Seattle, WA, United States of America

Dendreon Corporation


USPTO Granted Patents = 53



Trademarks = 4

Forward Citations = 503

Loading Chart...
Loading Chart...

92 inventors (with patents filed for the assignee):

goldMedal Reiner Laus (16 out of 17 patents)

silverMedal Edwin L Madison (7 out of 36 patents)

bronzeMedal Ofir Moreno (7 out of 17 patents)

4.  David Duncan (7 out of 10 patents)

5.  Lori A Jones (7 out of 8 patents)

6.  Odile Esther Levy (7 out of 29 patents)

7.  Thomas Graddis (6 out of 8 patents)

8.  Damir Vidovic (6 out of 6 patents)

9.  Sateesh Kumar Natarajan (6 out of 8 patents)

10.  Ashok Arasappan (5 out of 47 patents)

11.  Curtis L Ruegg (5 out of 18 patents)

12.  Stephane L Bogen (5 out of 48 patents)

13.  Edgar Ong (5 out of 20 patents)

14.  Tin-Yau Chan (5 out of 25 patents)

15.  F George Njoroge (5 out of 99 patents)


Core Competencies:
Cancer Immunotherapy
Natural Killer Cells
Tumor Antigens
HLA-DR Antibodies
Serine Protease Inhibitors
Dendritic Cell Immunotherapy
Alternative Reading Frame Polypeptides
Major Histocompatibility Complex
Neutrophil Inhibitors
Prostate Tumor Detection
Small-Molecule Modulators
Immunostimulatory Compositions

53 patents:

1. 10261091 - Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome (2019-04-16),
2. 9051385 - Compositions employing alternative reading frame polypeptides for the treatment of cancer and infectious disease (2015-06-09),
3. 8658177 - Promiscuous HER-2/Neu CD4 T cell epitopes (2014-02-25),
4. 8647865 - Promiscuous PAP CD4 T cell epitopes (2014-02-11),
5. 8618155 - Small-molecule modulators of Trp-p8 activity (2013-12-31),
6. 8614243 - Small-molecule modulators of Trp-p8 activity (2013-12-24),
7. 8540982 - Methods for inducing a natural killer (NK) cell-mediated immune response and for increasing NK cell activity (2013-09-24),
8. 8389730 - Compositions and methods for the treatment of disease associated with TRP-P8 expression (2013-03-05),
9. 8362264 - Compositions and methods for the treatment of disease associated with Trp-p8 expression (2013-01-29),
10. 8361479 - Promiscuous PAP CD4 T cell epitopes (2013-01-29),
11. 8354507 - HLA-DR specific antibodies, compositions and methods (2013-01-15),
12. 8263757 - Promiscuous HER-2/Neu CD4 T cell epitopes (2012-09-11),
13. 8153120 - Methods for inducing a natural killer (NK) cell-mediated immune response and for increasing NK cell activity (2012-04-10),
14. RE43298 - Peptides as NS3-serine protease inhibitors of hepatitis C virus (2012-04-02),
15. 7972602 - Promiscuous HER-2/Neu CD4 T cell epitopes (2011-07-05),
Dendreon Corporation is a biotechnology company focused on the discovery, development, and commercialization of innovative cancer treatments. Our mission is to improve the lives of cancer patients by harnessing the power of the immune system. We are proud to have developed the first FDA-approved autologous cellular immunotherapy for advanced prostate cancer patients. Through our innovative research and cutting-edge therapies, we strive to revolutionize cancer treatment and provide hope to patients worldwide.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

...
53 Patents

#43 in Seattle, WA

#131 in Washington

#6,438 in US

#12,943 in the World

...
Seattle, WA, United States of America

Dendreon Corporation

Forward Citations = 503

92 inventors:

goldMedal Reiner Laus (16 out of 17 patents)

silverMedal Edwin L Madison (7 out of 36 patents)

bronzeMedal Ofir Moreno (7 out of 17 patents)

4.  David Duncan (7 out of 10 patents)

5.  Lori A Jones (7 out of 8 patents)

Please report any incorrect information to support@idiyas.com
Loading…